Wednesday 30 July, 2008

Cinacalcet (Sensipar): Barr confirms Para IV Challenge to innovator's patents

Barr Pharma has challenged four orange book listed patents held by Amgen Inc. for its Cinacalcet or Sensipar (30, 60 and 90 mg tablets), used by dialysis patients to treat side-effects of the treatment. Innovator Amgen got approval on this product on Mar 8, 2004. Following are the Orange Book listed patents on this product:
US6011068 (Expiry: Dec 14, 2016)- Link
US6031003 (Expiry: Dec 14, 2016) Link
US6211244 (Expiry: Oct 23, 2015) Link
US6313146 (Expiry: Dec 14, 2016) Link
Sensipar or Cinacalcet (N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine) acts as a calcimimetic by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.
Barr said it filed ANDA with Para IV certification against Orange Book listed patents on Cinacalcet on March 10, 2008.
Sensipar recorded $377 million in U.S. sales during the 12 months ending May, Barr said.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker